Marc Halterman Issued New Patent
Friday, December 4, 2015
Congratulations to Dr. Marc Halterman on the outstanding achievement of a new patent for technology UR 6-1871 “Methods of Treatment and Screening Assays for HIF-1 Alpha Regulation” under Patent# 9,205,129.
Jennetta Hammond Wins Award for Basic science research conducted by a post-doctoral fellow
Wednesday, December 2, 2015
In celebration of World AIDS Day, held every year on December 1, the University of Rochester Center for AIDS Research (UR CFAR) hosted a scientific symposium. Guest lecturer Dan Barouch, M.D., Ph.D., professor of Medicine at Harvard Medical School, highlighted that the best hope for controlling the HIV/AIDS epidemic, which has claimed the lives of 39 million people around the world, is the development of a safe and effective vaccine. Barouch outlined the challenges of developing an HIV vaccine–there are many–and new strategies being studied, including an HIV vaccine pill that was tested at the University of Rochester Medical Center by infectious disease expert John J. Treanor, M.D., and HIV vaccine expert and co-director of the UR CFAR Michael C. Keefer, M.D.
Jennetta Hammond, a postdoctoral fellow in Dr. Harris Gelbard's lab, has won the award for basic science research conducted by a post-doctoral fellow at this year's symposium.
Congrats Jennetta!Read More: Jennetta Hammond Wins Award for Basic science research conducted by a post-doctoral fellow
Experimental Treatment Regimen Effective Against HIV
Monday, October 19, 2015
Protease inhibitors are a class of antiviral drugs that are commonly used to treat HIV, the virus that causes AIDS. Scientists at the University of Nebraska Medical Center designed a new delivery system for these drugs that, when coupled with a drug developed at the University of Rochester School of Medicine and Dentistry, rid immune cells of HIV and kept the virus in check for long periods. The results appear in the journal Nanomedicine: Nanotechnology, Biology and Medicine.
While current HIV treatments involve pills that are taken daily, the new regimens' long-lasting effects suggest that HIV treatment could be administered perhaps once or twice per year.
Nebraska researcher Howard E. Gendelman designed the investigational drug delivery system–a so–called
nanoformulated protease inhibitor. The nanoformulation process takes a drug and makes it into a crystal, like an ice cube does to water. Next, the crystal drug is placed into a fat and protein coat, similar to what is done in making a coated ice–cream bar. The coating protects the drug from being degraded by the liver and removed by the kidney.
When tested together with URMC–099, a new drug discovered in the laboratory of UR scientist Harris A. (Read More: Experimental Treatment Regimen Effective Against HIV
Handy) Gelbard M.D., Ph.D., the nanoformulated protease inhibitor completely eliminated measurable quantities of HIV. URMC–099 boosted the concentration of the nanoformulated drug in immune cells and slowed the rate at which it was eliminated, thereby prolonging its therapeutic effect.
Understanding the Enemy Within that Causes Brain Damage after Cardiac Arrest
Thursday, May 7, 2015
A new $1.7 million grant will bring together a team of researchers to study – an ultimately thwart – the chain reaction that occurs in the body after cardiac arrest that can ultimately lead to brain damage and death.
“While the biological sequence of events is triggered by cardiac arrest, the death and disability associated with this event is the result of a broader systemic injury caused the initial loss of blood flow and subsequent tissue inflammation once blood circulation is restored,” said University of Rochester Medical Center neurologist Marc Halterman, M.D., Ph.D., the principal investigator of the study. Read More: Understanding the Enemy Within that Causes Brain Damage after Cardiac Arrest
In fact, it is the cumulative effect of this systemic injury on the brain, and not the heart – that ultimately leads to mortality in the disorder.
URMC Start-up Takes Aim at Memory and Cognitive Problems
Thursday, April 30, 2015
Medications are available to treat many of the symptoms of neurodegenerative diseases like multiple sclerosis and Parkinson’s disease, but there is no drug or other therapy that improves the memory and cognitive problems that often plague patients. A new start-up company, built around research conducted at the University of Rochester School of Medicine and Dentistry, hopes to change that.
Camber NeuroTherapeutics Inc., founded based on discoveries made in the laboratories of Harris "Handy" A. Gelbard, M.D., Ph.D. and Stephen Dewhurst, Ph.D., plans to attack the cognitive component of neurodegenerative diseases using a completely new approach: stopping the inflammation in the brain, so-called neuroinflammation, that impairs the function of nerve cells and the vast networks they create. These neural networks allow us to store and recall memories, plan and prioritize, focus on particular tasks, and process sensory information.Read More: URMC Start-up Takes Aim at Memory and Cognitive Problems
Study Finds New Genetic Clues to Pediatric Seizure Disorders
Friday, April 3, 2015
Researchers have identified a new genetic mutation at the heart of a severe and potentially deadly seizure disorder found in infants and young children. The finding, which was reported today in the American Journal of Human Genetics, may help scientists unravel the complex biological mechanism behind these diseases.
These findings allow us to open up what was, up to this point, a black box and more fully understand the biological pathways associated with these disorders and why some individuals do not respond to treatment, said Alex Paciorkowski, M.D., an assistant professor of Neurology at the University of Rochester Medical Center (URMC) and lead author of the study.
Once the mutation was identified, the researchers worked with neurobiologists in the lab of Marc Halterman, M.D., Ph.D. in the URMC Center for Neural Development and Disease, and were able to identify the downstream impact of the mutation, namely that it regulated another gene that has been associated with severe seizures called myocyte-specific enhancer factor 2C (MEF2C).Read More: Study Finds New Genetic Clues to Pediatric Seizure Disorders